| Literature DB >> 34944409 |
Antonio Evidente1, Marco Masi1.
Abstract
Natural products are a vital source for agriculture, medicine, cosmetic and other fields. Among them alkylamides are a broad and expanding group found in at least 33 plant families. Frequently, they possess a simple carbon skeleton architecture but show broad structural variability and important properties such as immunomodulatory, antimicrobial, antiviral, larvicidal, insecticidal and antioxidant properties, amongst others. Despite to these several and promising biological activities, up to today, only two reviews have been published on natural alkylamides. One focuses on their potential pharmacology application and their distribution in the plant kingdom and the other one on the bioactive alkylamides specifically found in Annona spp. The present review is focused on the plant bioactive cinnamoyltyramine alkylamides, which are subject of several works reported in the literature. Furthermore, the co-metabolites isolated from the same natural sources and their biological activities are also reported.Entities:
Keywords: alkylamide; biological activity; cinnamoyltyramine; different carbon skeleton; plant sources
Mesh:
Substances:
Year: 2021 PMID: 34944409 PMCID: PMC8698393 DOI: 10.3390/biom11121765
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1General structure of an alkylamide.
Scheme 1Biosynthesis of cynnamic acids and tyramine from phenylalanine and tyrosine, respectively.
Scheme 2Biosynthesis of phenylalanine and tyrosine (Phe and Tyr) according to shikimic acid pathway.
Scheme 3Biosinthesis of N-trans-cinnamoyltyramine (1) by conjugation of cinnamoylCoA and tyramine.
Figure 2The structures of compounds 2–19.
Figure 3The structure of compounds 20–37.
Figure 4The structures of compounds 38–52.
Figure 5The structures of compounds 53–68.
Figure 6The structures of compounds 69–85.
Figure 7The structures of compounds 86–98.
Figure 8The structures of compounds 99–114.
Figure 9The structures of compounds 115–137.
Figure 10The structures of compounds 138–151.
Figure 11The structures of compounds 152–167.
Figure 12The structures of compounds 168–182.
Figure 13The structures of compounds 183–197.
Figure 14The structures of compounds 198–203.
Figure 15The structures of compounds 204–208.
Alkylamides, their sources and biological activities.
| Alkylamide | Source | Biological Activity | References |
|---|---|---|---|
|
| No activity | [ | |
| “ | [ | ||
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
| “ | [ | ||
|
| “ | [ | |
|
| Inhibition of pancreatic lipase | [ | |
|
| No activity | [ | |
|
| Inhibition of α-glucosidase | [ | |
|
| No activity | [ | |
|
| Inhibition of apoptosis and cytoprotective | [ | |
|
| No activity | [ | |
|
| “ | [ | |
| “ | [ | ||
|
| “ | [ | |
|
| Inhibition of thromboxane and prostaglandin synthetase | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| Anticancer activity and inhibition of protein tyrosine kinases | [ | |
|
| Inhibition of acetylcholinesterase | [ | |
|
| No activity | [ | |
|
| Antibiotic | [ | |
| No activity | [ | ||
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
| “ | [ | ||
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| Antidiabetic | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| Antidiabetic | [ | |
|
| Antiprotozoal | [ | |
|
| Moderate radical scavenging, anti-inflammatory and antidiabetic | [ | |
|
| No activity | [ | |
|
| Inhibition of pancreatic lipase | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| Inhibition of α-glucosidase | [ | |
|
| No activity | [ | |
|
| “ | [ | |
| “ | [ | ||
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| Inhibition of α-glucosidase | [ | |
|
| Moderate cytotoxicity | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| Inhibition of α-glucosidase | [ | |
|
| Hepatoprotective activity | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
| “ | [ | ||
|
| “ | [ | |
|
| Inhibition of NO production in RAW 264.7 cells | [ | |
| No activity | [ | ||
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
| “ | [ | ||
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| Radical scavenging | [ | |
|
| Antidiabetic | [ | |
|
| Antiprotozoal | [ | |
|
| Moderate radical scavenging, anti-inflammatory and antidiabetic | [ | |
|
| Anti-inflammatory | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| Inhibition of α-glucosidase | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| Inhibition of α-glucosidase | [ | |
|
| No activity | [ | |
|
| Inhibition of α-glucosidase | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
| “ | [ | ||
|
| “ | [ | |
|
| “ | [ | |
| “ | [ | ||
| “ | [ | ||
|
| “ | [ | |
| “ | [ | ||
| “ | [ | ||
|
| “ | [ | |
|
| “ | [ | |
|
| Cytoprotective | [ | |
|
| No activity | [ | |
| “ | [ | ||
|
| Inhibition of prostaglandin and thromboxane synthetase | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
|
| Antidiabetic | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| “ | [ | |
| “ | [ | ||
|
| “ | [ | |
|
| “ | [ | |
|
| “ | [ | |
| “ | [ | ||
|
| “ | [ | |
| “ | [ | ||
|
| “ | [ | |
|
| Antiprotozoal | [ | |
|
| Moderate radical scavengingNF-κB inhibitory | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| Cytoprotective | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| “ | [ | |
| 3′-Methoxy-NTFT ( |
| Radical scavenging | [ |
| 4′- |
| No activity | [ |
| 4′- |
| “ | [ |
|
| Moderate radical scavenging, anti-inflammatory and antidiabetic | [ | |
|
| No activity | [ | |
|
| “ | [ | |
|
| “ | [ | |
| “ | “ | “ | |
|
| “ | [ | |
| “ | “ | “ | |
| “ | “ | “ | |
| “ | “ | “ | |
| “ | “ | “ |
Co-metabolites, their sources, and biological activities.
| Metabolite | Source | Biological Activity | References |
|---|---|---|---|
| Grossamide ( | No activity | [ | |
| Hordatin A ( |
| Antifungal | [ |
| Hordatin B ( | “ | “ | “ |
| Hordatin M ( | “ | “ | “ |
| Lunularic acid ( |
| Inhibition of thromboxane and prostaglandin synthetase | [ |
| Rhapontigenin ( |
| “ | [ |
| Piceatannol, ( | “ | “ | “ |
| Rhaponticin ( | “ | “ | “ |
| Piceatannol glucoside ( | “ | “ | “ |
| Mandolin S ( |
| No activity | [ |
| Mandolin R ( | “ | “ | “ |
| Mandolin U ( | “ | “ | “ |
| Mandolin W ( | “ | “ | “ |
| Mandolin X ( | “ | “ | “ |
| Canusesnol A ( |
| Cytotoxic | [ |
| Canusesnol B ( | “ | No activity | “ |
| Canusesnol C ( | “ | “ | “ |
| Canusesnol D ( | “ | “ | “ |
| Canusesnol E ( | “ | “ | “ |
| Canusesnol F ( | “ | “ | “ |
| Canusesnol G ( | “ | “ | “ |
| Canusesnol H ( | “ | “ | “ |
| Canusesnol I ( | “ | “ | “ |
| Canusesnol J ( | “ | “ | “ |
| Aristolactam E ( |
| “ | [ |
| Aristolactam-AIIIa-6- | “ | “ | “ |
| Aristoquinoline A ( | “ | “ | “ |
| Aristoquinoline B ( | “ | “ | “ |
| Aristoquinoline C ( | “ | “ | “ |
| Aristogin F ( | “ | “ | “ |
| 2-Oxo-12-(3′,4′-methylenedioxyphenyl)dodecane ( |
| Antibiotic | [ |
| 2-Oxo-14-(3′,4′-methylenedioxyphenyl)tetradecane ( | “ | “ | “ |
| ( | “ | No activity | “ |
| 2-Oxo-18-(3′,4′-methylenedioxyphenyl)octadecane ( | “ | “ | “ |
| 2-Oxo-14-(3’,4’-methylenedioxyphenyl)- | “ | “ | “ |
| 2-Oxo-16-(3′,4′-methylenedioxyphenyl)- | “ | Antibiotic | “ |
| 2-Oxo-18-(3′,4′-methylenedioxyphenyl)- | “ | No activity | “ |
| 2-Oxo-16-phenyl- | “ | “ | “ |
| Methyl [6-(10-phenyldecanyl)tetrahydropyran-2-yl]acetate ( | “ | “ | “ |
| Methyl 2-(6-tridecyltetrahydro-2 | “ | “ | “ |
| Methyl 2-(5-tetradecyltetrahydro-2-furanyl)acetate ( | “ | “ | “ |
| 2-Oxo-14-(3′,4′-methylenedioxyphenyl)- | “ | “ | “ |
| 2-Oxo-16-(3′,4′-methylenedioxyphenyl)- | “ | “ | “ |
| 2-Oxo-16-phenyl-3-hexadecane ( | “ | “ | “ |
| Lignan |
| No activity | [ |
| Lignan | “ | “ | “ |
| Lignan | “ | Anticancer | “ |
| Lignan | “ | “ | “ |
| Lignan | “ | “ | “ |
| Lignan | “ | Anti-inflammatory | “ |
| Asiaticumine A ( | No activity | [ | |
| Asiaticumine B ( | “ | “ | “ |
| 4-Methyl-heptadec-6-enoic acid ethyl ester and ( |
| Antileishmanial | [ |
| 3-Hydroxy-2,9,11-trimethoxy-5,6-dihydro isoquino[3,2-a] isoquinolinylium ( | “ | “ | “ |
| 1-Nitrosoimino-2,4,5-trimethoxybenzene ( |
| Cytotoxic | [ |
| Alkaloid |
| No activity | [ |
| Alkaloid | “ | “ | “ |
| Alkaloid | “ | “ | “ |
| Alkaloid | “ | “ | “ |
| Eryciboside A ( |
| No activity | [ |
| Eryciboside B ( | “ | Hepatoprotective | “ |
| Eryciboside C ( | “ | No activity | “ |
| Eryciboside D ( | “ | “ | “ |
| Eryciboside E ( | “ | “ | “ |
| Eryciboside F ( | “ | Hepatoprotective | “ |
| Eryciboside G ( | “ | No activity | “ |
| Eryciboside H ( | “ | “ | “ |
| Eryciboside I ( | “ | “ | “ |
| Eryciboside J ( | “ | “ | “ |
| Eryciboside K ( | “ | “ | “ |
| Eryciboside L ( | “ | Hepatoprotective | “ |
| Chlorogenic acid derivative ( | “ | No activity | “ |
| Chlorogenic acid derivative ( | “ | “ | “ |
| Chlorogenic acid derivative ( | “ | “ | “ |
| Chlorogenic acid derivative ( | “ | “ | “ |
| Biscoumarin ( | “ | Hepatoprotective | “ |
| Kaempferol ( |
| No activity | [ |
|
| “ | [ | |
| Neolignanamide ( |
| Moderate radical scavenging | [ |
| Neolignanamide ( | “ | “ | “ |
| Neolignanamide ( | “ | “ | “ |
| Neolignanamide ( | “ | “ | “ |
| Neolignanamide ( | “ | “ | “ |
| Neolignanamide ( | “ | “ | “ |
| Neolignanamide ( | “ | “ | “ |
| Lignanamide ( | “ | “ | “ |
| Portulacaldehyde ( |
| No activity | [ |
| “ | Anti-inflammatory | “ | |
| Nelumnucifoside A ( |
| No activity | [ |
| Nelumnucifoside B ( | “ | “ | “ |
| Flavifloramide A ( |
| “ | [ |
| Flavifloramide B ( | “ | “ | “ |
| Aristoyunnolin I ( |
| “ | [ |
| Aristoyunnolin I ( | “ | “ | “ |
| Custonolide ( | “ | Moderate cytotoxicity | “ |
| Claulamine C ( |
| No activity | [ |
| Claulamine D ( | “ | “ | “ |
| Claulamine E ( | “ | “ | “ |
| Clausenaline B ( | “ | “ | “ |
| Clausenaline C ( | “ | “ | “ |
| Clausenaline D ( | “ | “ | “ |
| Clausenaline E ( | “ | “ | “ |
| Clausenaline F ( | “ | “ | “ |
| Clausemarins A ( | “ | Anti-inflammatory | “ |
| Clausemarin B ( | “ | No activity | “ |
| Clausemarin C ( | “ | “ | “ |
| Clausemarin D ( | “ | “ | “ |
| (3 |
| “ | [ |
| Sargentodoside A ( |
| “ | [ |
| Sargentodoside B ( | “ | “ | “ |
| Sargentodoside C ( | “ | “ | “ |
| Sargentodoside D ( | “ | “ | “ |
| Sargentodoside E ( | “ | “ | “ |
| Sargentodognan F ( | “ | “ | “ |
| Sargentodognan G ( | “ | “ | “ |
| 5,6-Dimethoxy-7-hydroxy-8-methyl-flavone ( |
| “ | [ |
| 5,6-Dimethoxy-8-methyl-2-phenyl-7 | “ | “ | “ |
| 4-Methoxy-6-(2-hydroxy-4-phenylbutyl)-2 | “ | “ | “ |
| 9,10-Dihydrophenanthrene-1,5-dihydroxy-3,4,7-trimethoxy-9,10-dihydrophenanthrene ( |
| “ | [ |
| Miliusacunine A ( |
| Antimalaria | [ |
| Miliusacunine B ( | “ | “ | “ |
| Miliusacunine C ( | “ | No activity | “ |
| Miliusacunine D ( | “ | “ | “ |
| Miliusacunine E ( | “ | “ | “ |
| 7-Methoxyflavonol ( |
| Radical scavenging | [ |
| 7-Methoxyflavonol ( | “ | Inhibition mushroom tyrosinase | “ |
| 7-Methoxyflavonol ( | “ | “ | “ |
| 7-Methoxyflavonol ( | “ | “ | “ |
| 7-Methoxyflavonol ( | “ | Radical scavenging | “ |
| Fisetinidol glucoside ( | “ | “ | “ |
| Benzyl glycoside ( | “ | “ | “ |
| Lyciumsterol A ( |
| No activity | [ |
| Lyciumsterol B ( | “ | Protective effects on pancreatic islet cells | “ |
| Lyciumsterol C ( | “ | “ | “ |
| Lyciumsterol D ( | “ | No activity | “ |
| Lyciumsterol E ( | “ | “ | “ |
| Lyciumsterol F ( | “ | Protective effects on pancreatic islet cells | “ |
| Lyciumsterol G ( | “ | Protective effects on pancreatic islet cells and autophagy activation | “ |
| Lyciumsterol H ( | “ | No activity | “ |
| Lyciumsterol I ( | “ | Autophagy activation | “ |
| Lyciumsterol J ( | “ | No activity | “ |
| Lyciumsterol K ( | “ | Autophagy activation | “ |
| (7 |
| No activity | [ |
| “ | “ | “ | |
| Aristolochic acid II alanine amide ( |
| “ | [ |
|
| “ | [ | |
| Ruthenicunoid A ( |
| Inhibition of SIRT1 | [ |
| Pseuduvarioside ( |
| No activity | [ |
| Oleraisoindole ( |
| Inhibited NO production in RAW 264.7 cells | [ |
| 2β,7,3-Trihydroxycalamenene 3- |
| Moderate cytotoxicity | [ |
| Bobulretulate A ( |
| No activity | [ |
| Bobulretulate B ( | “ | “ | “ |
| Majusamide A ( |
| “ | [ |
| Majusamide B ( | “ | “ | “ |
| Chelidoniumine ( | “ | “ | “ |
| Tetrahydrocoptisine- | “ | “ | “ |
| Dasymaschalolactam A ( |
| “ | [ |
| Dasymaschalolactam B ( | “ | “ | “ |
| Dasymaschalolactam C ( | “ | “ | “ |
| Dasymaschalolactam D ( | “ | “ | “ |
| Dasymaschalolactam E ( | “ | “ | “ |
| Dasymaschalolactone ( | “ | “ | “ |
| 4- |
| “ | [ |
| 4,12-di- | “ | “ | “ |
| Tinobaenzin A ( | “ | “ | “ |
| Tinobaenzin B ( | “ | “ | “ |
| 4- | “ | “ | “ |
| Goniochelienic acid A ( |
| “ | [ |
| Goniochelienic acid B ( | “ | “ | “ |
| Methyl goniochelienate ( | “ | “ | “ |
| Goniochelieninone ( | “ | “ | “ |
| (−)-(4 | “ | “ | “ |
| 7- | “ | “ | “ |
| (+)-(7 | “ | “ | “ |
| (−)-(7 | “ | “ | “ |
| Celtisamide A ( |
| “ | [ |
| Celtisamide B ( | “ | “ | “ |
| Dracaenogenin C ( |
| “ | [ |
| Dracaenogenin D ( | “ | “ | “ |
| Dracaenogenin E ( | “ | “ | “ |
| Dracaenogenin F ( | “ | “ | “ |
| 3′′-Methoxycochinchinenene H ( | “ | Anti-inflammatory | “ |
| Aristolochiaside ( |
| Cytotoxic | [ |
| Eloundemnoside ( |
| Moderate butyrylcholinesterase inhibition | [ |
| Fistuloimidate A ( |
| Antibiotic | [ |
| Fistuloimidate B ( | “ | “ | “ |
| 7 |
| No activity | [ |
| 7 | “ | Inhibited NO production in RAW 264.7 cells | “ |